Correlation Between BridgeBio Pharma and Inovio Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both BridgeBio Pharma and Inovio Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining BridgeBio Pharma and Inovio Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between BridgeBio Pharma and Inovio Pharmaceuticals, you can compare the effects of market volatilities on BridgeBio Pharma and Inovio Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in BridgeBio Pharma with a short position of Inovio Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of BridgeBio Pharma and Inovio Pharmaceuticals.

Diversification Opportunities for BridgeBio Pharma and Inovio Pharmaceuticals

0.34
  Correlation Coefficient

Weak diversification

The 3 months correlation between BridgeBio and Inovio is 0.34. Overlapping area represents the amount of risk that can be diversified away by holding BridgeBio Pharma and Inovio Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inovio Pharmaceuticals and BridgeBio Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on BridgeBio Pharma are associated (or correlated) with Inovio Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inovio Pharmaceuticals has no effect on the direction of BridgeBio Pharma i.e., BridgeBio Pharma and Inovio Pharmaceuticals go up and down completely randomly.

Pair Corralation between BridgeBio Pharma and Inovio Pharmaceuticals

Given the investment horizon of 90 days BridgeBio Pharma is expected to generate 1.14 times more return on investment than Inovio Pharmaceuticals. However, BridgeBio Pharma is 1.14 times more volatile than Inovio Pharmaceuticals. It trades about -0.01 of its potential returns per unit of risk. Inovio Pharmaceuticals is currently generating about -0.19 per unit of risk. If you would invest  3,070  in BridgeBio Pharma on September 9, 2024 and sell it today you would lose (191.00) from holding BridgeBio Pharma or give up 6.22% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

BridgeBio Pharma  vs.  Inovio Pharmaceuticals

 Performance 
       Timeline  
BridgeBio Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days BridgeBio Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, BridgeBio Pharma is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors.
Inovio Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Inovio Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

BridgeBio Pharma and Inovio Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with BridgeBio Pharma and Inovio Pharmaceuticals

The main advantage of trading using opposite BridgeBio Pharma and Inovio Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if BridgeBio Pharma position performs unexpectedly, Inovio Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inovio Pharmaceuticals will offset losses from the drop in Inovio Pharmaceuticals' long position.
The idea behind BridgeBio Pharma and Inovio Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Complementary Tools

Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Global Correlations
Find global opportunities by holding instruments from different markets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance